This week’s AI stock spotlight is Pfizer ($PFE)
Pfizer began in 1849 when Charles Pfizer and Charles Erhart, two German immigrants, opened a fine-chemicals shop in Brooklyn with a product that seems almost quaintly on-brand: an almond-flavored antiparasite medicine called santonin. From that modest beginning, Pfizer grew into one of the world’s largest pharmaceutical companies, surviving wars, depressions, patent cliffs, and the kind of corporate reinvention that would have killed lesser enterprises. The company’s modern era was defined by two events of opposite character. First, the COVID-19 pandemic turned Pfizer into the world’s largest pharmaceutical company by revenue, with Comirnaty and Paxlovid generating tens of billions in annual revenue during 2021 and 2022. Second, the post-pandemic decline of those same COVID-19 revenues created a revenue cliff that the company is still climbing out from under. Today Pfizer matters to traders because it sits at the intersection of a powerful turnaround story and a looming patent cliff, and Wall Street is now debating whether the pipeline can replace the revenue being lost faster than the market expected. All market data in this report is as of the market close on September 1, 2026.
Pfizer discovers, develops, manufactures, and distributes medicines and vaccines across four primary therapeutic areas: oncology, internal medicine, vaccines, and inflammation and immunology. Its product portfolio includes some of the most commercially significant drugs in pharmaceutical history. Eliquis, a blood thinner co-marketed with Bristol Myers Squibb, generated approximately $12 billion in 2024 sales and remains one of the most prescribed anticoagulants in the world. Padcev, a bladder cancer therapy acquired through the $43 billion Seagen acquisition in 2023, is expanding into earlier treatment lines. Vyndaqel treats a rare but devastating cardiac condition. Ibrance is a breast cancer therapy. Xtandi addresses prostate cancer. Nurtec, acquired through the Biohaven deal, is a fast-growing migraine treatment. And Comirnaty and Paxlovid, the COVID-19 vaccine and antiviral that defined Pfizer’s pandemic peak, are now in managed decline.
The company is headquartered at the Spiral, 66 Hudson Yards, New York, NY, and is led by Chairman and CEO Albert Bourla, who took the role in January 2019. Pfizer employs approximately 75,000 people globally. Bourla, a Greek-born veterinarian with a Ph.D. in the biotechnology of reproduction, joined Pfizer in 1993 and rose through positions in animal health, vaccines, and oncology before becoming CEO. Under his leadership, Pfizer divested non-science-based businesses, increased R&D investment, restructured into four end-to-end therapeutic units, and completed two transformative acquisitions: Seagen for $43 billion in 2023 and Metsera for up to $10 billion in 2025. Competitors include Merck, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, AbbVie, Roche, and Novartis. Pfizer’s distinction is its sheer scale and pipeline breadth, combined with a dividend yield that makes it one of the highest-yielding stocks in the S&P 500. While Eli Lilly and Novo Nordisk have captured the obesity market narrative, Pfizer is building a differentiated obesity pipeline through Metsera’s berobenatide, an ultra-long-acting GLP-1 receptor agonist designed for monthly dosing rather than weekly injections.
The financial history explains why Wall Street’s relationship with Pfizer has become complicated. Revenue has traveled an extraordinary arc — from $41.65 billion in 2020 to a peak of $100.33 billion in 2022, then collapsing to $59.55 billion in 2023 as COVID-19 revenues evaporated, before partially recovering to $63.63 billion in 2024 and settling at $62.58 billion in 2025. Net income followed an even more violent path: $9.16 billion in 2020, surging to $31.37 billion in 2022, then plummeting to $2.12 billion in 2023. The distinction matters. Pfizer’s revenue story is really two stories: a COVID-19 story that went from zero to $56 billion to declining, and an underlying business that has been growing steadily underneath the pandemic noise. Excluding COVID-19 products, revenues grew 6% operationally in 2025. The question is whether the underlying business is growing fast enough to replace what the pandemic took away and what the patent cliff will take next.
The numbers tell a story of a company in transition rather than decline. Revenue declined 2% operationally in 2025, but adjusted diluted EPS actually rose to $3.22 from $3.11 in 2024, suggesting that cost-cutting and portfolio optimization are protecting profitability even as top-line revenue compresses. Pfizer has achieved $4.5 billion in savings by the end of 2025, with a path toward $7.7 billion in net savings by 2027. The company also announced an additional $2.5 billion in cost-cutting during its Q2 2026 earnings, targeting $9.7 billion in total net savings through 2029. That is not merely cost-trimming. That is a structural reshaping of the operating model.
Traders are really asking two questions now. First, can Pfizer’s pipeline , particularly in oncology, obesity, and immunology, generate enough new revenue to offset the patent cliff that threatens Eliquis, Ibrance, and Xtandi between 2026 and 2028? Second, is the market undervaluing a company with a forward P/E of approximately 9.5 to 10.2 (midpoint ~9.8) and a 6% dividend yield, or are those metrics a value trap signaling that Wall Street expects growth to remain anemic? Those are considerably more useful questions than asking whether Pfizer will ever return to its pandemic-era revenue levels.
The evidence supporting the bulls has been accumulating. First-quarter 2026 revenues reached $14.5 billion, up 5% year-over-year, with launched and acquired products growing 22% operationally. Second-quarter 2026 revenues came in at $15.03 billion, up 3% reported and 1% operationally, with non-COVID products growing 5% and launched and acquired products growing 18%. Adjusted diluted EPS of $0.77 beat the consensus estimate of $0.68 by nine cents. Eliquis sales rose 21% to $2.43 billion in Q2, well above analyst estimates of $1.93 billion. Padcev sales rose 23% to $667 million. Management consequently raised the midpoint of full-year 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion, while reaffirming adjusted diluted EPS guidance of $2.80 to $3.00. That is not merely a good quarter for a pharmaceutical company in transition. That is evidence that the post-COVID reconstruction is ahead of schedule.
The most important news of the last 30 days has been less about a single press release and more about a convergence of signals. On August 4, Pfizer reported Q2 results that topped estimates on both revenue and adjusted earnings. On August 27, Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine for the 2026-2027 season. The Metsera obesity pipeline is advancing rapidly, with ten pivotal studies expected to progress in 2026 for berobenatide, which demonstrated 12.0% to 12.3% placebo-corrected weight loss at week 28 in Phase 2b comparing favorably to digitized estimates for weekly semaglutide (~9.0%) and tirzepatide (~12.5%). The Innovent Biologics deal, worth up to $10.5 billion, expanded Pfizer’s oncology pipeline with 12 early-stage cancer drug candidates. And the MEVPRO-1 Phase 3 trial for mevrometostat in prostate cancer is fully enrolled with a readout expected in Q4 2026.
Some of this optimism is obviously reflected in the stock price. Through September 1, PFE had gained approximately 20.6% year-to-date on a total-return basis and approximately 23.4% over the trailing year. The S&P 500 returned approximately 18.1% over the same trailing-year period. PFE is not merely participating in a market rally. It is outperforming the benchmark it was widely expected to trail. The Health Care Select Sector SPDR ETF, XLV, has lagged the broader market, making Pfizer’s relative strength even more notable against its sector headwinds.
Why? Earnings beats, raised guidance, pipeline execution, cost-cutting momentum, a 6% dividend yield, and the growing belief that Pfizer’s transformation from a COVID-dependent company back to a diversified biopharmaceutical leader is real. The obesity pipeline from Metsera, the oncology portfolio from Seagen, and the immunology expansion from the Biohaven and Innovent deals are giving investors something they have not had in years: a reason to believe in future growth rather than merely managing decline.
That is also where Wall Street could be wrong. Pfizer carries an enormous overhang: the patent cliff. Eliquis, which generated over $12 billion in 2024 revenue, faces European patent expiry already underway and U.S. generic entry expected in April 2028. Ibrance, Xtandi, and other key products face patent expirations in 2027. Analysts estimate that Pfizer could lose $17 to $20 billion in annual revenue to generic competition between 2026 and 2030. At a forward P/E of approximately 9.5 to 10.2, the market is pricing in significant concern about this cliff. The question is whether the market is pricing in too much concern or not enough.
The upside opportunity is substantial but contingent. If the pipeline delivers, berobenatide in obesity, mevrometostat in prostate cancer, the Innovent oncology programs, continued Padcev and Eliquis strength before generic entry, Pfizer could generate high single-digit revenue CAGR from 2028 through 2033, as management has targeted. A monthly GLP-1 in a market projected to reach $150 billion would be transformative. A successful mevrometostat readout in Q4 2026 would add a major oncology franchise. And the 6% dividend yield provides a substantial cushion while waiting for the pipeline to deliver. The biggest upside surprise would be evidence that berobenatide can compete meaningfully against Eli Lilly and Novo Nordisk in obesity. That would fundamentally re-rate the stock.
The biggest risk is exactly the patent cliff wearing a convincing disguise. Eliquis generic entry in Europe is already underway. U.S. generic entry in April 2028 is less than 20 months away. If pipeline readouts disappoint, cost-cutting reaches its natural limits, or COVID-19 revenues decline faster than expected, investors may suddenly remember that they are holding a stock whose growth depends on products that have not yet been approved. The 6% dividend yield, while attractive, also reflects a payout ratio that exceeds 100% of GAAP earnings, meaning the dividend is being funded partly by adjusted earnings and cost savings rather than reported net income. That is sustainable for now, but it is not permanent.
The catalyst calendar is unusually dense. The MEVPRO-1 Phase 3 readout for mevrometostat in prostate cancer is expected in Q4 2026, a major binary event. The talazoparib plus enzalutamide combination is advancing through regulatory review with a target action date expected in Q4 2026. Ten pivotal studies for berobenatide are progressing throughout 2026. Third-quarter 2026 earnings are expected in early November. The next dividend payment was made on September 1, 2026. And the ongoing Eliquis European patent expiry will create quarterly revenue headwinds that investors need to monitor. Earnings and pipeline readouts matter most because traders will discover whether the post-COVID reconstruction is accelerating or stalling.
The company is performing better than the market expected. The stock has noticed. That means the risk is no longer whether Pfizer can stabilize. The risk is whether the pipeline can grow fast enough to replace the revenue the patent cliff will take away. At a forward P/E of approximately 9.5 to 10.2 and a 6% dividend yield, the market is pricing in significant pessimism. That creates opportunity for patient investors, but it also raises the burden of proof. Pipeline execution, not cost-cutting, will determine whether Pfizer re-rates higher or remains stuck in value-stock purgatory.
PFE therefore looks best suited to value and income investors comfortable with pipeline risk, not growth-chasers expecting a return to pandemic-era revenue levels. The trend can continue if non-COVID revenue grows, the pipeline delivers on its catalysts, and the dividend remains sustainable. The turnaround is real. Whether it is enough depends on what the next 18 months of data reveal.
The early warning sign is simple: watch non-COVID revenue growth and pipeline readouts before listening to the cost-cutting story. If those weaken together, especially alongside disappointing clinical results, respect the message. Pharmaceutical pipelines are binary. Patent cliffs are not. And at roughly 9.5 to 10.2 times forward earnings, Pfizer may offer a high yield and a low valuation, but nobody should confuse a value stock with a risk-free investment.
Wall Street Analysts Annual Forecasts
Before deciding whether to be bullish or bearish on Pfizer, it helps to see what Wall Street’s professional fortune-tellers are saying. These analysts watch PFE constantly, study the clinical data, question management and then somehow arrive at answers separated by $10. The most bullish target is $35.00. The most bearish is $25.00. With PFE closing at $28.55, that is a meaningful range of opinion.
Wall Street is not confused about whether Pfizer is a major pharmaceutical company. It is confused about whether the pipeline can replace the patent cliff. That disagreement is valuable because it tells traders that even the experts cannot agree on what Pfizer’s future revenue will look like.
The math makes the disagreement clear. Take the $35.00 high target, subtract the $25.00 low target, and divide the $10.00 difference by the current $28.55 price. You get an analyst-disagreement reading of approximately 35.0%. Meanwhile, the average analyst target of $28.28 sits approximately 0.9% below the current price. That may be the most important number on the page. PFE has rallied enough that the stock has essentially caught Wall Street’s consensus forecast. The analysts are no longer debating whether Pfizer can stabilize. They are debating whether the pipeline can grow.
For traders, that’s where things get interesting. PFE has a high dividend yield, a low forward valuation, improving non-COVID fundamentals, and exceptional cost-cutting momentum. But the average analyst is effectively saying, “Show me the pipeline.” The opportunity lies in the gap between the $28.55 current price and the $35.00 bull case. Successful clinical readouts, continued non-COVID growth, and evidence that berobenatide can compete in obesity could force analysts to raise targets and re-rate the stock. Disappointing data or faster-than-expected generic erosion could send the argument toward the bears because the market’s pessimism would be confirmed. This remains a value and income investor’s setup, but 35.0% disagreement among Wall Street analysts is a reminder that the range of outcomes for Pfizer is exceptionally wide.
52 Week High and Low Boundaries Analysis
Another powerful way to understand volatility is to forget predictions and study what PFE has already done. Over the past 52 weeks, the stock traveled from roughly $23.58 to $29.09, a $5.51 trading range. Divide that range by the current $28.55 price and you get a range-to-price ratio of 19.3%. This is not the same as annualized historical volatility (which is approximately 21% based on daily price changes), but it provides a useful measure of how much PFE has traveled over the past year relative to its current price. Put simply, PFE covered a distance equal to roughly one-fifth of its current price during the past year. Today it sits in the 90.2nd percentile of that range, just $0.54 below its 52-week high. That tells you immediately where the pressure is. Buyers are in control, momentum has improved, and PFE is behaving like a stock that has rediscovered investor interest.
The midpoint of the 52-week range is approximately $26.34. What matters is what happened next. PFE broke above that middle zone and marched toward the top of its range. If we use the stock’s 19.3% historical volatility as a rough stress test and apply it around the $26.34 midpoint, we get extreme theoretical boundaries of roughly $31.42 and $21.26. Those are not forecasts. They simply remind us that this stock, despite its low beta of approximately 0.40, has demonstrated an ability to travel a meaningful distance when investor sentiment shifts.
Now comes the part traders need to respect. PFE is strong, but strength in a pharmaceutical stock carries different risks than strength in a high-beta momentum stock. At the 90th percentile of its annual range, you are buying near the top of a range that was established over the past year. A clean breakout above $29.09 would put PFE into new 52-week-high territory and confirm that the trend remains intact. A rejection at the highs followed by sustained weakness would tell us something has changed, with the $26.34 midpoint becoming an important longer-term reference point. For value and income investors, the setup remains attractive because the dividend yield provides a real return while waiting. But with a 19.3% historical range and a pipeline full of binary catalysts, risk management is not optional. The trend says stay interested. The catalyst calendar says stay alert.
Best-Case/Worst-Case Analysis
Pfizer has been teaching traders an important lesson: a pharmaceutical turnaround does not travel in a straight line. The best-case scenario shows the stock recovering from its 2025 lows near $23.58 to above $28.55, an advance of roughly 21%, driven by earnings beats, raised guidance, pipeline progress, and cost-cutting momentum. Earlier advances from the COVID-era lows of 2020 to the all-time high near $59 in 2021 demonstrated that PFE can deliver spectacular moves when investor sentiment aligns with fundamental catalysts. The most recent advance, from the low-$24s to above $28.50, represents the market’s initial recognition that the post-COVID reconstruction is working.
But here’s what the bulls cannot afford to ignore. PFE has also experienced significant drawdowns. The stock declined approximately 57% from its December 2021 peak near $59 to its 2024 lows. The COVID-19 revenue collapse drove a multi-year decline that punished late buyers. The important lesson is not whether the next drawdown will be 10% or 30%. Nobody knows. The lesson is that pharmaceutical stocks with binary pipeline catalysts and patent cliff overhangs can experience sharp repricing when clinical trials fail or generic competition arrives faster than expected.
So here’s the line in the sand. As long as PFE continues making higher highs and the non-COVID revenue base keeps growing, the bulls have the fundamental argument. A clean move above $29.09 strengthens that case. The danger appears when the character changes: pipeline readouts disappoint, generic erosion accelerates, or the dividend coverage comes into question. That would tell us the stock is no longer merely correcting inside an uptrend. It may be transitioning into something more dangerous.
The biggest mistake here would be looking at PFE’s 6% dividend yield and 9.5 to 10.2 forward P/E and concluding that the stock is safe. It isn’t. Value is not safety. The historical record says PFE can deliver meaningful advances and painful corrections. Value and income investors have the advantage while the pipeline continues to deliver and non-COVID revenue grows, but they also need an exit plan before the market gives them a reason to use it.
That’s the trade in one sentence: respect the turnaround, but remember what happens when a pipeline readout fails.
VantagePoint AI Predictive Blue Line
The Predictive Blue Line is VantagePoint’s predicted moving average, while the black line represents the actual moving average. When the blue line moves above the black line and both begin rising, the market is essentially putting up a green road sign saying buyers have the advantage.
Watch the distance between the blue and black lines. When the blue line stays above the black line, the forecast is stronger than the recent historical trend. When that gap expands while both lines are rising, bullish momentum is accelerating.
For traders, the message is simple: don’t argue with a rising Predictive Blue Line. As long as the blue line remains above the black line and its slope remains positive, the evidence favors the bulls and pullbacks deserve attention as potential opportunities rather than automatic reasons to sell. The first warning would be the blue line flattening while price struggles to advance. A stronger warning would be the blue line turning down and crossing beneath the black line.
VantagePoint AI Neural Index
The Neural Index is designed to forecast short-term price strength or weakness over roughly the next 48 to 72 hours. Green signals indicate anticipated strength, while red signals warn of potential short-term weakness. That distinction matters. The Predictive Blue Line tells us the broader trend, while the Neural Index helps traders judge whether the immediate market conditions are confirming or contradicting that trend.
VantagePoint AI Daily Range Forecast
The Daily Range Forecast is where prediction becomes practical. Pfizer is not a high-volatility stock. Its average trading range is approximately 2.0% per day, with an implied volatility of approximately 21% annualized. Those numbers tell traders something important before the opening bell: PFE routinely gives you less room to make money than a high-beta momentum stock, but it also gives you less room to be wrong. A 2.0% average daily range means that on a $28.55 stock, a normal day’s high-to-low movement can represent roughly $0.57. That is not a forecast that PFE will move $0.57 tomorrow. It is a useful measure of the territory this stock has historically been capable of covering.
This is where VantagePoint’s Daily Range Forecast becomes especially valuable. On the chart, the predicted high and predicted low create a forecast range around each trading session. Instead of asking the vague question, “How high can PFE go today?” the trader gets defined price boundaries to work with.
The real advantage comes when the Daily Range Forecast is combined with the other predictive indicators. In that environment, the predicted low becomes particularly interesting as a potential value zone during temporary weakness, while the predicted high provides a logical area for traders to consider taking profits or tightening risk. But remember the numbers: approximately 2.0% daily, with an annualized volatility of approximately 21%. PFE has been rewarding patient investors with a substantial dividend and improving price action, but it carries enough pipeline binary risk to punish anyone who confuses a value stock with a risk-free trade. The forecast gives you the boundaries. The trend tells you which side deserves your attention.
Intermarket Analysis
Intermarket analysis is like looking under the hood instead of simply admiring the paint job. PFE does not trade alone. The graphic shows connections to healthcare markets, pharmaceutical ETFs, large-cap value stocks, the S&P 500, Treasuries, gold, oil, the U.S. dollar and major currencies. It also connects PFE with individual companies that VantagePoint’s intermarket analysis identifies as having meaningful statistical relationships to PFE’s price behavior. The important point is not that each market causes PFE to rise or fall. Rather, VantagePoint’s intermarket analysis identifies markets with meaningful statistical relationships to PFE’s price behavior. And buried inside these relationships traders will often discover other market gems they were not originally watching.
PFE’s price action is connected not simply to pharmaceutical competitors but to interest rates, currencies, commodities, broader equity indexes, and healthcare sector flows. That matters because a pharmaceutical company’s fortunes can change when borrowing costs move, healthcare policy shifts, or money rotates between defensive and growth assets. The network tells us what to watch. Price and predictive indicators tell us whether those relationships are presently helping or hurting.
For traders, that makes intermarket analysis an early-warning system. If PFE remains strong while its important related markets and predictive indicators continue confirming the move, confidence in the trend increases. If those relationships begin deteriorating while PFE continues making new highs, that divergence deserves attention because the stock may be running ahead of its supporting forces. That argues for respecting the trend, while using the intermarket network to watch for cracks before they become obvious on the price chart. Strong trends rarely travel alone.
Our Suggestion
Pfizer presents one of those situations traders love and fear at the same time: the fundamentals are improving, but the market is pricing in significant uncertainty about the future. Revenue traveled from $41.65 billion in 2020 to a peak of $100.33 billion in 2022, then declined to $62.58 billion in 2025 as COVID-19 revenues collapsed. Net income followed a similar arc, from $9.16 billion in 2020 to $31.37 billion in 2022, then settling at $7.77 billion in 2025. The important change is that the underlying business, excluding COVID-19 products, grew 6% operationally in 2025, and adjusted diluted EPS actually rose to $3.22 from $3.11. That matters because it demonstrates that Pfizer’s cost-cutting and portfolio optimization are protecting profitability even as top-line revenue compresses.
Pfizer’s management sounds confident because it has been delivering results, not simply making promises. First-quarter 2026 revenue rose 5% to $14.5 billion, with launched and acquired products growing 22% operationally. Second-quarter 2026 revenue reached $15.03 billion, with adjusted diluted EPS of $0.77 beating the consensus by nine cents. Management raised the midpoint of full-year 2026 revenue guidance by $500 million to $60.5 billion to $62.5 billion, while reaffirming adjusted EPS guidance of $2.80 to $3.00. The company also announced $2.5 billion in additional cost cuts, targeting $9.7 billion in total net savings through 2029. Management believes the pipeline: in oncology, obesity, immunology, and vaccines, is advancing on schedule, but it remains cautious about generic competition, healthcare policy, COVID-19 revenue decline, and clinical trial risk.
The important issue for traders is that expectations remain low. The forward P/E of approximately 9.5 to 10.2 and the 6% dividend yield reflect a market that is skeptical about the pipeline’s ability to replace the patent cliff. Pfizer has been rewarding that skepticism with improving non-COVID revenue growth, cost-cutting execution, and pipeline progress. That creates an opportunity. If clinical readouts deliver, particularly the mevrometostat Phase 3 in Q4 2026 and the berobenatide obesity program, the market may need to re-rate PFE significantly higher. If they disappoint, the market’s pessimism will be confirmed and the stock could retest its lows.
The Daily Range Forecast adds an important warning: PFE historically moves approximately 2.0% daily with an annualized volatility of approximately 21%. This is lower volatility than a high-beta momentum stock, but it carries enough pipeline binary risk to require disciplined position sizing.
Wall Street provides perhaps the clearest picture of the opportunity and the argument against it. Using the targets supplied in this study, analysts range from $25.00 to $35.00, with an average target of $28.28. The $10.00 spread represents approximately 35.0% of PFE’s current price, showing meaningful disagreement about what comes next. More telling, the consensus target is actually slightly below the current market price. In other words, PFE has essentially caught Wall Street’s average forecast, while the most optimistic analysts still see substantial upside. That creates opportunity, but it also raises the burden of proof. Pipeline readouts, non-COVID revenue growth, and cost-cutting execution increasingly need to justify what the stock price has already begun to reflect.
Our suggestion is therefore to respect the turnaround without underestimating the patent cliff. PFE currently checks several boxes we want in a value and income opportunity: improving non-COVID fundamentals, a high dividend yield, a low forward valuation, strong cost-cutting momentum, and a pipeline full of potential catalysts. A decisive move through $29.09 would establish fresh 52-week highs and strengthen the bullish case. But this stock has also demonstrated that pharmaceutical pipelines are binary, clinical trial failures can reprice a stock overnight. At the 90th percentile of its annual range, the risk is no longer hidden.
The next major catalysts are the mevrometostat MEVPRO-1 readout expected in Q4 2026 and the ongoing berobenatide pivotal studies throughout 2026. Third-quarter earnings in early November will also provide an important test of whether the non-COVID growth trajectory is accelerating. Management has earned credibility, but now it must continue delivering against a backdrop of patent cliff headwinds.
Practice great money management on every trade, and use the VantagePoint AI Daily Range Forecast to identify short-term trading opportunities while keeping risk firmly under control.
It’s not magic.
It’s machine learning.
Disclaimer: THERE IS A HIGH DEGREE OF RISK INVOLVED IN TRADING. IT IS NOT PRUDENT OR ADVISABLE TO MAKE TRADING DECISIONS THAT ARE BEYOND YOUR FINANCIAL MEANS OR INVOLVE TRADING CAPITAL THAT YOU ARE NOT WILLING AND CAPABLE OF LOSING.
VANTAGEPOINT’S MARKETING CAMPAIGNS, OF ANY KIND, DO NOT CONSTITUTE TRADING ADVICE OR AN ENDORSEMENT OR RECOMMENDATION BY VANTAGEPOINT AI OR ANY ASSOCIATED AFFILIATES OF ANY TRADING METHODS, PROGRAMS, SYSTEMS OR ROUTINES. VANTAGEPOINT’S PERSONNEL ARE NOT LICENSED BROKERS OR ADVISORS AND DO NOT OFFER TRADING ADVICE.
